%D8%A3%D8%AA%D9%88%D9%81%D8%A7%D9%83%D9%88%D9%8A%D9%86Category:AtovaquoneAtofacwonAtovaquonAtovaquoneAtovaquonaAtovakoniAtovaquoneAtovaquone%E3%82%A2%E3%83%88%E3%83%90%E3%82%B3%E3%83%B3AtovaquoneAtowakwonAtovaquonaAtovaquon%C4%83%D0%90%D1%82%D0%BE%D0%B2%D0%B0%D0%BA%D1%83%D0%BE%D0%BDAtovaksonAtovakson%D0%90%D1%82%D0%BE%D0%B2%D0%B0%D0%BA%D0%B2%D0%BE%D0%BDAtovaquoneQ418179
about
P3781
Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)Ototoxicity of Artemether / Lumefantrine (Coartem) and Other AntimalarialsDrug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected PatientsEvaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory FunctionAzithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South AmericaSevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum MalariaAtovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2Safety and Efficacy of NF135 CPS ImmunizationDrug Combinations of Atovaquone-Proguanil (AP) With ACTEvaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated MalariaChemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous InfectionTarget Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under ChemoprophylaxisDSM265 Chemoprophylaxis of Plasmodium Falciparum MalariaThe ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in CambodiaAntiretroviral Drug Interaction Study in Volunteers With HIVA Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy VolunteersChloroquine (CQ) and Azithromycin (AZ) Combination for Malaria ProphylaxisSingle Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone SuspensionWeekly Dosing of Malarone ® for Prevention of MalariaChloroquine Alone or in Combination for Malaria in Children in MalawiA Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMXA Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / SulfamethoxazoleA Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-SulfadiazineA Treatment IND for 566C80 Therapy of Pneumocystis Carinii PneumoniaAn Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral PentamidineA Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive ChildrenA Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or SulfonamidesPhase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic EncephalitisPhase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and ChildrenA Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS PatientsDetermine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P ChemoprophylaxisControlled Human Malaria Infection Model for Evaluation of Transmission‐Blocking Interventions - Study 1Atovaquone as Tumour HypOxia ModifierEffect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
P4844
Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domainMolecular basis for atovaquone binding to the cytochrome bc1 complex.Antimalarial pharmacology and therapeutics of atovaquoneInhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation.NADH-ubiquinone oxidoreductase activity in the kinetoplasts of the plant trypanosomatid Phytomonas serpens.Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae.An alkaline comet assay study on the antimalarial drug atovaquone in human peripheral blood lymphocytes: a study based on clinically relevant concentrations.Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid
P921
Q61915282-594722E7-BA30-469B-AADD-209AAC718D79Q61920986-C2EEEBC0-84BF-43E0-88B0-1AAA967AA377Q61921867-344C2C63-DF0D-43E3-BD65-C108CA2A0DD3Q61924784-29AB8CA8-F7A2-413D-B729-734277B4F242Q62110768-C607B5DC-00EB-4683-8E92-362BE55C26DEQ63322206-E61278B6-D30E-47CD-A390-A1E44B90009FQ63397688-A26F0531-C489-41E9-8D39-30FE8C4C8CE5Q63400554-30118A37-5F3D-431B-94AA-5B4558A934E8Q63582884-F2172BEA-79DF-4321-BF88-C6391A2147E1Q63597110-A874A6FE-AA77-405C-B205-6CDDD5CAE89FQ63829770-27BBF6AC-2854-4CE8-8417-A2914BF0720CQ64220054-4CFB413C-F0F5-40DB-8B45-3DA423CDF2D4Q64221878-966684A5-62F7-4203-A6E4-04A7AE644A7CQ64364131-AEC85A07-2DD6-459C-A429-D9F3CAEEB753Q64613675-020281C6-212E-401D-9050-58B213C0E753Q64647652-EE5F36ED-7CF7-4469-B62A-B7291D1BE17FQ64658164-40E85391-0C3D-4FA7-AAE8-FD0945995164Q64818889-1FD50DC1-BFC6-4FFD-8517-569B8A436CE6Q65366969-11D76CE7-576D-499E-92DA-5BD1C5533728Q65377314-AC6969C9-8E0E-4D97-AA14-69C6E0EC3B37Q65388291-94484318-9419-46DF-96A3-01DC6BA160F8Q66040224-12226656-A847-4C11-9E2D-B382DFC8B6FCQ66040570-7AAB6BC8-E3BC-4401-B7A7-A70DDD395755Q66040572-E7DB33A9-F4FB-4CC4-AE0D-49EDA6ED348DQ66040575-5EF578B1-01D8-4F7F-B9F2-746754C9E7EAQ66040576-1450B749-C1E0-4D14-9EEE-565FB549C809Q66040908-73666183-6C14-450D-8502-790CBB5677F6Q66040917-AA12F2D4-6E55-4850-B02A-3F42C4CDAC5CQ66040925-F7FB2F97-C8A7-4D88-96CC-ED1E85EA4CCCQ66040944-2D69DB47-9F35-4A87-AA3C-32AF2C7FB490Q66041064-BC40A05F-2D83-4E6E-A372-445C47E83D1CQ66064193-FF2148B1-DC83-4ACD-A971-E429B91069AAQ66395156-2949272F-88EC-4B47-8A7D-B4B05BDE264DQ66399827-632B8183-A4DE-4DCF-8463-7672F5BEF738Q66410951-801E379B-D776-42E2-93BA-95643D3D8C37Q67125678-77019475-AD10-4923-9152-FD92EAD838E0Q80364099-012BAA40-A7AA-4331-9E01-DF9B735DE5ECQ90693341-430DFB4F-95FA-4914-8CEA-700FEBF5A717
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Atovakoni
@fi
Atovakson
@sh
Atovakson
@sr
Atovaquon
@de
Atovaquona
@es
Atovaquone
@nl
Atovaquone
@vi
Atovaquonă
@ro
atofacwon
@cy
atovaquona
@pt
type
label
Atovakoni
@fi
Atovakson
@sh
Atovakson
@sr
Atovaquon
@de
Atovaquona
@es
Atovaquone
@nl
Atovaquone
@vi
Atovaquonă
@ro
atofacwon
@cy
atovaquona
@pt
altLabel
2-(trans-4-(P-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
@cy
2-(trans-4-(P-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
@en
566C
@cy
566C
@en
566C80
@cy
566C80
@en
95233-18-4
@fr
Acuvel
@cy
Acuvel
@en
Atovaquone
@en
prefLabel
Atovakoni
@fi
Atovakson
@sh
Atovakson
@sr
Atovaquon
@de
Atovaquona
@es
Atovaquone
@nl
Atovaquone
@vi
Atovaquonă
@ro
atofacwon
@cy
atovaquona
@pt